Skip to main content
Top
Published in: Tumor Biology 12/2014

01-12-2014 | Research Article

A functional variant at miR-34a binding site in toll-like receptor 4 gene alters susceptibility to hepatocellular carcinoma in a Chinese Han population

Authors: Zi-Cheng Jiang, Xian-Mei Tang, Ying-Ren Zhao, Lei Zheng

Published in: Tumor Biology | Issue 12/2014

Login to get access

Abstract

Toll-like receptor 4 (TLR4) plays a key role in prompting the innate or immediate response. A growing body of evidence suggests that genetic variants of TLR4 gene were associated with the development of cancers. This study aimed to investigate the relationship of a functional variant (rs1057317) at microRNA-34a (miR-34a) binding site in toll-like receptor 4 gene and the risk of hepatocellular carcinoma. A single center-based case–control study was conducted. In this study, the polymerase chain reaction (PCR) and direct sequencing were used to genotype sequence variants of TLR4 in 426 hepatocellular carcinoma cases and 438 controls. The modification of rs1057317 on the binding of hsa-miR-34a to TLR4 messenger RNA (mRNA) was measured by luciferase activity assay. Individuals carrying the AA genotypes for the rs1057317 were associated significantly with increased risk of hepatocellular carcinoma comparing with those carrying wild-type homozygous CC genotypes (adjusted odds ratio [OR] by sex and age, from 1.116 to 2.452, P = 0.013). The activity of the reporter vector was lower in the reporter vector carrying C allele than the reporter vector carrying A allele. Furthermore, the expression of TLR4 was detected in the peripheral blood mononucleated cell of hepatocellular carcinoma (HCC) patients, suggesting that mRNA and protein levels of TLR4 might be associated with SNP rs1057317. Collectively, these results suggested that the risk of hepatocellular carcinoma was associated with a functional variant at miR-34a binding site in toll-like receptor 4 gene. miR-34a/TLR4 axis may play an important role in the development of hepatocellular carcinoma.
Literature
1.
go back to reference Wang Z, Cao Y, Jiang C, Yang G, Wu J, Ding Y. Lack of association of two common polymorphisms rs2910164 and rs11614913 with susceptibility to hepatocellular carcinoma: a meta-analysis. PLoS One. 2012;7:e40039.CrossRef Wang Z, Cao Y, Jiang C, Yang G, Wu J, Ding Y. Lack of association of two common polymorphisms rs2910164 and rs11614913 with susceptibility to hepatocellular carcinoma: a meta-analysis. PLoS One. 2012;7:e40039.CrossRef
2.
go back to reference Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, et al. Hepatocellular carcinoma: consensus recommendations of the national cancer institute clinical trials planning meeting. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:3994–4005.CrossRef Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, et al. Hepatocellular carcinoma: consensus recommendations of the national cancer institute clinical trials planning meeting. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:3994–4005.CrossRef
3.
go back to reference Gao J. Association of MDR1 gene polymorphisms with the risk of hepatocellular carcinoma in the Chinese Han population. Braz J Med Biol Res = Rev Bras Pesquisas Med Biologicas Soc Bras Biofisica. 2013;46:311–7. Gao J. Association of MDR1 gene polymorphisms with the risk of hepatocellular carcinoma in the Chinese Han population. Braz J Med Biol Res = Rev Bras Pesquisas Med Biologicas Soc Bras Biofisica. 2013;46:311–7.
4.
go back to reference Bi J, Zhong C, Li K, Chu H, Wang B. Association study of single nucleotide polymorphisms in XRCC1 gene with risk of hepatocellular carcinoma in Chinese Han population. BioMed Res Int. 2013;2013:138785.PubMedPubMedCentral Bi J, Zhong C, Li K, Chu H, Wang B. Association study of single nucleotide polymorphisms in XRCC1 gene with risk of hepatocellular carcinoma in Chinese Han population. BioMed Res Int. 2013;2013:138785.PubMedPubMedCentral
5.
go back to reference Schutte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma–epidemiological trends and risk factors. Dig Dis. 2009;27:80–92.PubMed Schutte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma–epidemiological trends and risk factors. Dig Dis. 2009;27:80–92.PubMed
6.
go back to reference Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist. 2010;15 Suppl 4:14–22.CrossRef Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist. 2010;15 Suppl 4:14–22.CrossRef
7.
go back to reference Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6:674–87.CrossRef Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6:674–87.CrossRef
8.
go back to reference Suriawinata A, Xu R. An update on the molecular genetics of hepatocellular carcinoma. Semin Liver Dis. 2004;24:77–88.CrossRef Suriawinata A, Xu R. An update on the molecular genetics of hepatocellular carcinoma. Semin Liver Dis. 2004;24:77–88.CrossRef
9.
go back to reference Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol WJG. 2008;14:4300–8.CrossRef Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol WJG. 2008;14:4300–8.CrossRef
10.
go back to reference Zhao C, Yan F, Wu H, Qiao F, Qiu X, Fan H. DNMT3A -448A>G polymorphism and the risk for hepatocellular carcinoma. Biomed Rep. 2013;1:664–8.CrossRef Zhao C, Yan F, Wu H, Qiao F, Qiu X, Fan H. DNMT3A -448A>G polymorphism and the risk for hepatocellular carcinoma. Biomed Rep. 2013;1:664–8.CrossRef
11.
go back to reference Hu Z, Zhou Z, Xiong G, Wang Y, Lai Y, Deng L, et al. Cyclin D1 G870A polymorphism and the risk of hepatocellular carcinoma in a Chinese population. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2014;35(6):5607–12.CrossRef Hu Z, Zhou Z, Xiong G, Wang Y, Lai Y, Deng L, et al. Cyclin D1 G870A polymorphism and the risk of hepatocellular carcinoma in a Chinese population. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2014;35(6):5607–12.CrossRef
12.
go back to reference Zhang L, Qin H, Guan X, Zhang K, Liu Z. The TLR9 gene polymorphisms and the risk of cancer: evidence from a meta-analysis. PLoS One. 2013;8:e71785.CrossRef Zhang L, Qin H, Guan X, Zhang K, Liu Z. The TLR9 gene polymorphisms and the risk of cancer: evidence from a meta-analysis. PLoS One. 2013;8:e71785.CrossRef
13.
go back to reference Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science. 2010;327:291–5.CrossRef Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science. 2010;327:291–5.CrossRef
14.
go back to reference Wang RF, Miyahara Y, Wang HY. Toll-like receptors and immune regulation: implications for cancer therapy. Oncogene. 2008;27:181–9.CrossRef Wang RF, Miyahara Y, Wang HY. Toll-like receptors and immune regulation: implications for cancer therapy. Oncogene. 2008;27:181–9.CrossRef
15.
go back to reference Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature. 2000;406:782–7.CrossRef Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature. 2000;406:782–7.CrossRef
16.
go back to reference Kutikhin AG. Association of polymorphisms in TLR genes and in genes of the toll-like receptor signaling pathway with cancer risk. Hum Immunol. 2011;72:1095–116.CrossRef Kutikhin AG. Association of polymorphisms in TLR genes and in genes of the toll-like receptor signaling pathway with cancer risk. Hum Immunol. 2011;72:1095–116.CrossRef
17.
go back to reference Xu Y, Ma H, Yu H, Liu Z, Wang LE, Tan D, et al. The miR-184 binding-site rs8126 T>C polymorphism in TNFAIP2 is associated with risk of gastric cancer. PLoS One. 2013;8:e64973.CrossRef Xu Y, Ma H, Yu H, Liu Z, Wang LE, Tan D, et al. The miR-184 binding-site rs8126 T>C polymorphism in TNFAIP2 is associated with risk of gastric cancer. PLoS One. 2013;8:e64973.CrossRef
18.
go back to reference Minmin S, Xiaoqian X, Hao C, Baiyong S, Xiaxing D, Junjie X, et al. Single nucleotide polymorphisms of toll-like receptor 4 decrease the risk of development of hepatocellular carcinoma. PLoS One. 2011;6:e19466.CrossRef Minmin S, Xiaoqian X, Hao C, Baiyong S, Xiaxing D, Junjie X, et al. Single nucleotide polymorphisms of toll-like receptor 4 decrease the risk of development of hepatocellular carcinoma. PLoS One. 2011;6:e19466.CrossRef
19.
go back to reference Dang Y, Luo D, Rong M, Chen G. Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET. PLoS One. 2013;8:e61054.CrossRef Dang Y, Luo D, Rong M, Chen G. Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET. PLoS One. 2013;8:e61054.CrossRef
20.
go back to reference Chen T, Huang Z, Wang L, Wang Y, Wu F, Meng S, et al. MicroRNA-125a-5p partly regulates the inflammatory response, lipid uptake, and ORP9 expression in oxLDL-stimulated monocyte/macrophages. Cardiovasc Res. 2009;83:131–9.CrossRef Chen T, Huang Z, Wang L, Wang Y, Wu F, Meng S, et al. MicroRNA-125a-5p partly regulates the inflammatory response, lipid uptake, and ORP9 expression in oxLDL-stimulated monocyte/macrophages. Cardiovasc Res. 2009;83:131–9.CrossRef
21.
go back to reference Xu J, Yin Z, Gao W, Liu L, Yin Y, Liu P, et al. Genetic variation in a microRNA-502 minding site in SET8 gene confers clinical outcome of non-small cell lung cancer in a Chinese population. PLoS One. 2013;8:e77024.CrossRef Xu J, Yin Z, Gao W, Liu L, Yin Y, Liu P, et al. Genetic variation in a microRNA-502 minding site in SET8 gene confers clinical outcome of non-small cell lung cancer in a Chinese population. PLoS One. 2013;8:e77024.CrossRef
22.
go back to reference Wang K, Li J, Guo H, Xu X, Xiong G, Guan X, et al. MiR-196a binding-site SNP regulates RAP1A expression contributing to esophageal squamous cell carcinoma risk and metastasis. Carcinogenesis. 2012;33:2147–54.CrossRef Wang K, Li J, Guo H, Xu X, Xiong G, Guan X, et al. MiR-196a binding-site SNP regulates RAP1A expression contributing to esophageal squamous cell carcinoma risk and metastasis. Carcinogenesis. 2012;33:2147–54.CrossRef
23.
go back to reference Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y, et al. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett. 2009;275:44–53.CrossRef Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y, et al. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett. 2009;275:44–53.CrossRef
24.
go back to reference Duan W, Xu Y, Dong Y, Cao L, Tong J, Zhou X. Ectopic expression of miR-34a enhances radiosensitivity of non-small cell lung cancer cells, partly by suppressing the LyGDI signaling pathway. J Radiat Res. 2013;54:611–9.CrossRef Duan W, Xu Y, Dong Y, Cao L, Tong J, Zhou X. Ectopic expression of miR-34a enhances radiosensitivity of non-small cell lung cancer cells, partly by suppressing the LyGDI signaling pathway. J Radiat Res. 2013;54:611–9.CrossRef
25.
go back to reference Ji Q, Hao X, Meng Y, Zhang M, Desano J, Fan D, et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer. 2008;8:266.CrossRef Ji Q, Hao X, Meng Y, Zhang M, Desano J, Fan D, et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer. 2008;8:266.CrossRef
26.
go back to reference Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D, et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 2010;70:5923–30.CrossRef Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D, et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 2010;70:5923–30.CrossRef
27.
go back to reference Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E, et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res. 2009;69:7569–76.CrossRef Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E, et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res. 2009;69:7569–76.CrossRef
28.
go back to reference Weeraratne SD, Amani V, Neiss A, Teider N, Scott DK, Pomeroy SL, et al. miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro-Oncology. 2011;13:165–75.CrossRef Weeraratne SD, Amani V, Neiss A, Teider N, Scott DK, Pomeroy SL, et al. miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro-Oncology. 2011;13:165–75.CrossRef
29.
go back to reference Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A. 2010;107:264–9.CrossRef Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A. 2010;107:264–9.CrossRef
30.
go back to reference Sun F, Fu H, Liu Q, Tie Y, Zhu J, Xing R, et al. Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett. 2008;582:1564–8.CrossRef Sun F, Fu H, Liu Q, Tie Y, Zhu J, Xing R, et al. Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett. 2008;582:1564–8.CrossRef
31.
go back to reference Wei JS, Song YK, Durinck S, Chen QR, Cheuk AT, Tsang P, et al. The MYCN oncogene is a direct target of miR-34a. Oncogene. 2008;27:5204–13.CrossRef Wei JS, Song YK, Durinck S, Chen QR, Cheuk AT, Tsang P, et al. The MYCN oncogene is a direct target of miR-34a. Oncogene. 2008;27:5204–13.CrossRef
32.
33.
go back to reference El-Omar EM, Ng MT, Hold GL. Polymorphisms in toll-like receptor genes and risk of cancer. Oncogene. 2008;27:244–52.CrossRef El-Omar EM, Ng MT, Hold GL. Polymorphisms in toll-like receptor genes and risk of cancer. Oncogene. 2008;27:244–52.CrossRef
34.
go back to reference Zheng SL, Augustsson-Balter K, Chang B, Hedelin M, Li L, Adami HO, et al. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the cancer prostate in Sweden study. Cancer Res. 2004;64:2918–22.CrossRef Zheng SL, Augustsson-Balter K, Chang B, Hedelin M, Li L, Adami HO, et al. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the cancer prostate in Sweden study. Cancer Res. 2004;64:2918–22.CrossRef
35.
go back to reference Chen YC, Giovannucci E, Lazarus R, Kraft P, Ketkar S, Hunter DJ. Sequence variants of toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res. 2005;65:11771–8.CrossRef Chen YC, Giovannucci E, Lazarus R, Kraft P, Ketkar S, Hunter DJ. Sequence variants of toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res. 2005;65:11771–8.CrossRef
36.
go back to reference Song J, Kim DY, Kim CS, Kim HJ, Lee DH, Lee HM, et al. The association between toll-like receptor 4 (TLR4) polymorphisms and the risk of prostate cancer in Korean men. Cancer Genet Cytogenet. 2009;190:88–92.CrossRef Song J, Kim DY, Kim CS, Kim HJ, Lee DH, Lee HM, et al. The association between toll-like receptor 4 (TLR4) polymorphisms and the risk of prostate cancer in Korean men. Cancer Genet Cytogenet. 2009;190:88–92.CrossRef
37.
go back to reference Hold GL, Rabkin CS, Chow WH, Smith MG, Gammon MD, Risch HA, et al. A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology. 2007;132:905–12.CrossRef Hold GL, Rabkin CS, Chow WH, Smith MG, Gammon MD, Risch HA, et al. A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology. 2007;132:905–12.CrossRef
38.
go back to reference Hishida A, Matsuo K, Goto Y, Mitsuda Y, Hiraki A, Naito M, et al. Toll-like receptor 4 +3725 G/C polymorphism, Helicobacter pylori seropositivity, and the risk of gastric atrophy and gastric cancer in Japanese. Helicobacter. 2009;14:47–53.CrossRef Hishida A, Matsuo K, Goto Y, Mitsuda Y, Hiraki A, Naito M, et al. Toll-like receptor 4 +3725 G/C polymorphism, Helicobacter pylori seropositivity, and the risk of gastric atrophy and gastric cancer in Japanese. Helicobacter. 2009;14:47–53.CrossRef
Metadata
Title
A functional variant at miR-34a binding site in toll-like receptor 4 gene alters susceptibility to hepatocellular carcinoma in a Chinese Han population
Authors
Zi-Cheng Jiang
Xian-Mei Tang
Ying-Ren Zhao
Lei Zheng
Publication date
01-12-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2547-z

Other articles of this Issue 12/2014

Tumor Biology 12/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine